ERBB2 and breast carcinoma: Recently, data from the prospective, open-label, multicentre phase-II SOLTI-1303 PATRICIA trial showed that palbociclib in combination with trastuzumab is safe and results in longer PFS in trastuzumab pre-treated ER+/HER2+ advanced breast cancer with a PAM50 luminal subtype (12.4 months vs 4.1 months; P = 0.025) (Ciruelos et al. 2020).